Beyond the Headlines: A Single Dose, A Multi-Decade Question The immediate euphoria surrounding VERVE-102’s interim Phase I results—a staggering 62 percent reduction in LDL cholesterol—misses the most critical elephant in the biotech lab. Read More
August 9, 2026